Insights Center
Thought leadership, news, events — you will find them all here, right at your fingertips. We’ve consolidated the firm’s most popular content in one, easy to search location. Enter a key word or phrase to find pertinent blog posts, articles, press releases, and upcoming events.
Mintz Direct
Mintz Viewpoints
Showing 1889 - 1896 of 12089 results
DoJ Filing In Moderna Patent Case Poses Immunity Questions
February 22, 2023| News
CalPERS Fossil Fuel Divestment Bill Hinges On Union Support (1)
February 22, 2023| News
MintzTech Connect: All Things Technology — February 2023
February 21, 2023| Article| Viewpoint
Federal Judge Allows Antitrust Claims to Proceed Against Hospital System and Vertically-Integrated Physician Group
February 21, 2023| Blog| Viewpoint
Federal Court Kicks California Arbitration Ban to the Curb
February 21, 2023| Blog| Viewpoint
CMS Proposes New Disclosure of Ownership Regulations for Nursing Facilities - Top Five Takeaways for Private Equity Firms and REITs
February 21, 2023| Blog| Viewpoint
The Rise of Whistleblower Tips (and Rewards) for Crypto Sleuths
February 17, 2023| Blog| Viewpoint
Fifth Circuit Provides New Guidance on Evaluating Confidential Witnesses
February 16, 2023| Blog| Viewpoint
News & Press Releases
Mintz advised the creators of Morbid, one of the top-charting true crime podcasts, in a multi-year agreement to move to SiriusXM from Wondery. The deal gives SiriusXM exclusive advertising rights for the audio and video formats of the podcast.
Mintz Advises CVC DIF in Acquisition of SBA Communications’ Canadian Tower Infrastructure Platform
August 06, 2025
Mintz advised CVC DIF, the dedicated infrastructure investment strategy of global private markets manager CVC, in its agreement to acquire SBA Communications’ Canadian wireless tower business, one of Canada’s leading independent owners and operators of wireless communications towers. The transaction is expected to close in the fourth quarter of 2025, subject to customary closing conditions.
Mintz advised the underwriters in connection with a $69 million public offering by Larimar Therapeutics, Inc. of 21,562,500 shares of its common stock at a price to the public of $3.20 per share. The gross proceeds to Larimar from the offering were $69 million before deducting underwriting discounts and commissions and other offering expenses.
Events
Podcasts
Mintz On Air: Practical Policies — A Private Equity Non-Compete Primer
July 15, 2025| Podcast|
Health Law Diagnosed – Best Practices for Communicating with the FDA
July 9, 2025| Podcast|